Chemistry: molecular biology and microbiology – Measuring or testing process involving enzymes or... – Involving antigen-antibody binding – specific binding protein...
Reexamination Certificate
2007-11-27
2007-11-27
Saoud, Christine J. (Department: 1647)
Chemistry: molecular biology and microbiology
Measuring or testing process involving enzymes or...
Involving antigen-antibody binding, specific binding protein...
C435S007100, C435S007210, C435S007200, C424S139100, C424S156100
Reexamination Certificate
active
10509975
ABSTRACT:
The present invention relates to new uses of Solute Carrier 6 (SC6), a taurine transporter, in the diagnosis, screening, treatment and prophylaxis of hypoxia related conditions e.g. cancer. Compositions comprising the protein, such as vaccines and agents that modulate the protein expression or activity, including antibodies that are immunospecific for the protein, are also provided.
REFERENCES:
patent: 5658786 (1997-08-01), Smith et al.
patent: 6225115 (2001-05-01), Smith et al.
patent: 0982400 (2000-03-01), None
patent: WO 93/18143 (1993-09-01), None
patent: WO 01/077389 (2001-10-01), None
patent: WO 01/090148 (2001-11-01), None
patent: WO 01/090148 (2001-11-01), None
patent: WO 02/064798 (2002-08-01), None
patent: WO 02/098467 (2002-12-01), None
Wells, J.A. (1990). Additivity of mutational effects in proteins. Biochemistry. 29(37):8509-8517.
Ngo et al. (1994). Computational complexity, protein structure prediction, and the Levinthal paradox. In Merz and Le Grand (Eds.) The Protein Folding Problem and Tertiary Structure Prediction. Birkhauser:Boston, pp. 491-495.
Ramamoorthy, S., etal., Functional characterization and chromosomal localization of a cloned taurine transporter from human placenta, 1994, Biochem J., 300 (Pt 3), pp. 893-900.
Stapleton, PP, etal., Host Defense-A Role for the Amino Acid Taurine?, 1998, J Parenter Enteral Nutr., Jan.-Feb., 22(1), pp. 42-48.
Schaffer, S, etal., Role of osmoregulation in the actions of taurine, 2000, Amino Acids, 19(3-4), pp. 527-546.
Canas, PE, The Role Of Taurine And Its Derivatives On Celluar Hypoxia: A Physiological View, Acta Physiol Pharmacol Ther Latinoam, 42(3), pp. 133-137.
Michalk, DV, etal., The Mechanisms Of Taurine Mediated Protection Against Cell Damage Induced by Hypoxia And Reoxygenation, 1996, Adv Exp Med Biol, 403, pp. 223-232.
Saransaari, P., etal., Taurine and neural cell damage, 2000, Amino Acids 19 (3-4), pp. 509-526.
Niitynen, L, etal., Role of arginine, taurine and homocysteine in cardiovascular diseases, 1999, Ann Med, Oct.;31(5), pp. 318-326.
Brown, JM, Exploiting the hypoxic cancer cell: mechanisms and therapeutic strategies, 2000, Mol Med Today 6; pp. 157-162.
Database EMBL Online EBI; Feb. 1, 1993, Jiang et al., Accession No. Z18956.1; XP002264290.
Chinnaswamy Tiruppathy, etal., Constitutive expression of the taurine transporter in a human colon carcinoma cell line, 1992, Amer. J. Physiol. 263: G625-G631.
Han, X, etal., Is TauT a Target Gene of the WT1 Tumor Suppressor Gene?, J. Amer. Soc. Nephrology, 2000, vol. 11: Program & Abstract Issue pp. 43A-44A.
Han, X., etal., Regulation of the Taurine Transporter Gene (TauT) by the WT1 Tumor Suppressor Gene, Joint Meeting of the Pediatric Academic Societies and the American Academy of Pediatrics, Boston, MA, May 12-16, 2000, ISSN: 0031-3998 Abstract.
Klauber & Jackson L.L.C.
Lockard Jon M
Saoud Christine J.
UCB Pharma S.A.
LandOfFree
SC6 for diagnosis of cancers does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with SC6 for diagnosis of cancers, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and SC6 for diagnosis of cancers will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3876304